Initial experience with long-acting risperidone microspheres injection

✍ Scribed by Nicholas Keks; Cyril Been; Russell D’Souza; Rajan Thomas; Philip Tune; Jenny Babb; Edwina Brennan; Judy Hope

• Book ID: 104469991
• Publisher: Informa plc
• Year: 2003
• Tongue: English
• Weight: 82 KB
• Volume: 11
• Category: Article
• ISSN: 1039-8562
• DOI: 10.1046/j.1440-1665.2003.00577.x

✦ Synopsis

Objective: To report initial clinical experience with the injectable long-acting microspheres formulation of the atypical antipsychotic risperidone.

Methods: Case reports.

Results: The seven patients described have had good outcomes to date. A patient who has received the drug for 2 years has improved from a state of severe deterioration to full-time employment and participation in a relationship; he has reported mild erectile difficulties but is keen to continue. In all cases extrapyramidal side-effects have been uncommon and brief; weight gain or other physical adverse events have not been observed.

Conclusion: Initial use of long-acting injectable risperidone suggests that the first ‘atypical depot’ is a welcome therapeutic development likely to provide significant clinical benefits, particularly for patients who have previously had unsatisfactory experiences with conventional antipsychotics.